![]() |
|
|
Vol. 291, Issue 3, 1220-1226, December 1999
Departments of Pharmacology and Toxicology (G.J.R., K.A.B., S.M.O.)
and Anesthesiology (W.B.G.), College of Medicine,
University of Arkansas for Medical Sciences, Little Rock, Arkansas
The purpose of these studies was to better understand the behavioral
effects and pharmacokinetics of an i.v. bolus dose of (+)-methamphetamine [(+)-METH] in a rat model of (+)-METH abuse. We
characterized the behavioral effects after increasing (+)-METH doses
(0.1, 0.3, and 1.0 mg/kg) and the pharmacokinetics of (+)-METH (and its
metabolite (+)-amphetamine [(+)-AMP)]) at the lowest and highest of
these doses in adult male Sprague-Dawley rats. The doses and route of
administration were selected to mimic aspects of human use on a
dose/body weight basis. Although the 0.1 mg/kg dose did not cause
statistically significant increases in locomotor activity compared with
saline controls, the higher doses (0.3 and 1.0 mg/kg) caused
statistically significant increases in locomotor activity
(p < .05), which lasted for up to 3 h at the
highest dose. After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and
63.0 min, respectively. Because the pharmacokinetic values after the
0.1 mg/kg dose were not different from those after the 1.0 mg/kg dose,
the pharmacokinetics of (+)-METH were considered to be independent of
the dose over this 10-fold range. (+)-AMP serum concentrations after
the 1.0 mg/kg dose peaked from 10 to 30 min, and exhibited a
T1/2
z of 98.5 min. The statistically longer T1/2
z of (+)-AMP
(p < .05) suggested that the (+)-AMP terminal
elimination rate and not the (+)-AMP metabolic formation rate is the
rate-limiting step in (+)-AMP elimination following i.v. (+)-METH dosing.
This article has been cited by other articles:
![]() |
J. Treweek, S. Wee, G. F. Koob, T. J. Dickerson, and K. D. Janda Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease PNAS, July 10, 2007; 104(28): 11580 - 11584. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Laurenzana, K. A. Byrnes-Blake, A. Milesi-Halle, W. B. Gentry, D. K. Williams, and S. M. Owens USE OF ANTI-(+)-METHAMPHETAMINE MONOCLONAL ANTIBODY TO SIGNIFICANTLY ALTER (+)-METHAMPHETAMINE AND (+)-AMPHETAMINE DISPOSITION IN RATS Drug Metab. Dispos., November 1, 2003; 31(11): 1320 - 1326. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Rivière, W. B. Gentry, and S. M. Owens Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1042 - 1047. [Abstract] [Full Text] |
||||